[go: up one dir, main page]

WO2006116541A3 - Tat-002 and methods of assessing and treating cancer - Google Patents

Tat-002 and methods of assessing and treating cancer Download PDF

Info

Publication number
WO2006116541A3
WO2006116541A3 PCT/US2006/015904 US2006015904W WO2006116541A3 WO 2006116541 A3 WO2006116541 A3 WO 2006116541A3 US 2006015904 W US2006015904 W US 2006015904W WO 2006116541 A3 WO2006116541 A3 WO 2006116541A3
Authority
WO
WIPO (PCT)
Prior art keywords
tat
expression
methods
identification
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/015904
Other languages
French (fr)
Other versions
WO2006116541A2 (en
Inventor
Heather Butler
Sajani Swamy
Lyes Hamaidi
Marcelo Filgueira
Daniel Chelsky
Joel Lanoix
Kevin Eng
Pierre Thibault
Denis Faubert
Navdeep Jaitly
Sylvain Brunet
Frank R M Aguilera
John S-C Tsang
Michael Hu
Joachim B Ostermann
Marguerite Boulos
Paul E Kearney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thallion Pharmaceuticals Inc
Original Assignee
Caprion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caprion Pharmaceuticals Inc filed Critical Caprion Pharmaceuticals Inc
Publication of WO2006116541A2 publication Critical patent/WO2006116541A2/en
Publication of WO2006116541A3 publication Critical patent/WO2006116541A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Surprisingly, the present inventors have discovered that expression of TAT-002 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-002 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-002 expression or activity, comprising: contacting a candidate compound with a TAT-002 and detecting the presence or absence of binding between said compound and said TAT-002, or detecting a change in TAT-002 expression or activity. Methods are also included for the identification of compounds that modulate TAT-002 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-002 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.
PCT/US2006/015904 2005-04-27 2006-04-27 Tat-002 and methods of assessing and treating cancer Ceased WO2006116541A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67519105P 2005-04-27 2005-04-27
US60/675,191 2005-04-27
US67675205P 2005-04-29 2005-04-29
US60/676,752 2005-04-29

Publications (2)

Publication Number Publication Date
WO2006116541A2 WO2006116541A2 (en) 2006-11-02
WO2006116541A3 true WO2006116541A3 (en) 2007-04-19

Family

ID=37215470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/015904 Ceased WO2006116541A2 (en) 2005-04-27 2006-04-27 Tat-002 and methods of assessing and treating cancer

Country Status (1)

Country Link
WO (1) WO2006116541A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110946114A (en) * 2019-12-06 2020-04-03 福建正大食品有限公司 Camellia chicken feeding method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087831A2 (en) * 2002-04-11 2003-10-23 Oxford Glycosciences (Uk) Ltd Proteins involved in breast cancer
US20030220240A1 (en) * 2000-12-21 2003-11-27 Tang Y. Tom Vesicle trafficking proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220240A1 (en) * 2000-12-21 2003-11-27 Tang Y. Tom Vesicle trafficking proteins
WO2003087831A2 (en) * 2002-04-11 2003-10-23 Oxford Glycosciences (Uk) Ltd Proteins involved in breast cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AGRAWAL N. ET AL.: "RNA Interference: Biology, Mechanism, and Application", MICRO MOL. BIOL. REV., vol. 67, 2003, pages 657 - 685, XP009030438 *

Also Published As

Publication number Publication date
WO2006116541A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
Zhang et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
Swayampakula et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion
Hadzic et al. The role of low molecular weight thiols in T lymphocyte proliferation and IL-2 secretion
WO2009005809A3 (en) Compositions and methods for treating and diagnosing cancer
NO20074389L (en) Determination of responders to chemotherapy
CL2007003649A1 (en) An anti-cd70 human monoclonal antibody associated molecule conjugate; composition comprising the antibody-associated molecule conjugate; method of inhibiting the growth of tumor cells expressing cd70.
WO2011119934A3 (en) Methods and materials for detecting colorectal neoplasm
MY162056A (en) Diagnosis and treatment of cancer using anti -ereg antibody
AU2012283775A8 (en) Inhibitors of Bruton's tyrosine kinase
MX2010004251A (en) Anti-bst2 antibody.
MX357972B (en) Material and methods for treating or preventing her-3 associated diseases.
MX2010005651A (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof.
Greening et al. Colon tumour secretopeptidome: insights into endogenous proteolytic cleavage events in the colon tumour microenvironment
ATE514090T1 (en) USE OF THE PROTEIN SATB2 AS A MARKER TO DIFFERENTIATE COLORECTAL CARCINOMA FROM OTHER CANCER DISEASES
MX339340B (en) Methods for predicting and improving the survival of gastric cancer patients.
WO2009073575A3 (en) Methods for treating induced cellular proliferative disorders
WO2007087263A3 (en) Human zip1, zinc and citrate for prostate cancer screening
IL218442A0 (en) Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma
WO2003055908A3 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2006083957A3 (en) Tat-001 and methods of assessing and treating cancer
WO2006116681A3 (en) Tat-003 and methods of assessing and treating cancer
WO2007055966A3 (en) Therapies for cancer using rlip76
WO2006133145A3 (en) Tat-007 and methods of assessing and treating cancer
WO2006116541A3 (en) Tat-002 and methods of assessing and treating cancer
WO2007089793A3 (en) Tat-041 and methods of assessing and treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06758642

Country of ref document: EP

Kind code of ref document: A2